Sex-specific Augmentation of Treatment Responses in Bladder Cancer

Affiliations

¹ School of Medicine, University of California-San Francisco, San Francisco, CA, USA.
² Department of Urology, University of California-San Francisco, San Francisco, CA, USA.

Editorial

Kevin Chang et al. Eur Urol Open Sci. 2022.

. 2022 Oct 26:46:43-44.

doi: 10.1016/j.euros.2022.10.009. eCollection 2022 Dec.

¹ School of Medicine, University of California-San Francisco, San Francisco, CA, USA.
² Department of Urology, University of California-San Francisco, San Francisco, CA, USA.

No abstract available

Comment on

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment.
Besançon M, Gris T, Joncas FH, Picard V, Bergeron A, Fradet Y, Toren P. Besançon M, et al. Eur Urol Open Sci. 2022 Jul 26;43:35-44. doi: 10.1016/j.euros.2022.06.007. eCollection 2022 Sep. Eur Urol Open Sci. 2022. PMID: 36246841 Free PMC article.

1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
1. Scosyrev E., Noyes K., Feng C., Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2009;115:68–74. doi: 10.1002/cncr.23986. - DOI - PubMed
1. Besançon M., Gris T., Joncas F.-H., et al. Combining antiandrogens with immunotherapy for bladder cancer treatment. Eur Urol Open Sci. 2022;43:35–44. doi: 10.1016/j.euros.2022.06.007. - DOI - PMC - PubMed
1. Ardiani A., Gameiro S.R., Kwilas A.R., Donahue R.N., Hodge J.W. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget. 2014;5:9335–9348. doi: 10.18632/oncotarget.2429. - DOI - PMC - PubMed
1. de Jong J.J., Boormans J.L., van Rhijn B.W.G., et al. Distribution of molecular subtypes in muscle-invasive bladder cancer is driven by sex-specific differences. Eur Urol Oncol. 2020;3:420–423. doi: 10.1016/j.euo.2020.02.010. - DOI - PubMed